First Patient Enrolled in Phase 2 Clinical Trial + QIDP & Fast Track

Jun 7, 2021 | Press Releases

June 7, 2021 – Announcement:

Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel Antibiotic CRS3123 to Treat C. difficile Infections.

FDA also Grants CRS3123 ‘Qualified Infectious Disease Product’ (QIDP) and ‘Fast Track’ Designations.

Learn More:

https://www.businesswire.com/news/home/20210607005013/en/Crestone-Inc.-Enrolls-First-Patient-in-Phase-2-Clinical-Trial-for-Novel-Antibiotic-CRS3123-to-Treat-C.-difficile-Infections

Become a Part of Our Projects

Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor, a team member, or a participant in our ongoing clinical studies.

Inquiries

Have a question or comment? Follow the link below to contact us about general inquiries.

Contact Us

Careers

Find work in a team-oriented environment at one of the leading Colorado pharma companies.

Join Crestone

Investors

If you're interested in becoming an investor to help fund our research and development, contact us today.

Contact Us